A PYMNTS Company

EU: Johnson & Johnson offers concessions over Actelion deal

By  |  May 18, 2017

US healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion (ATLN.S), the European Commission said on Thursday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The EU competition enforcer extended its review of the deal to June 12 from May 24, according to a filing on its website. It did not provide details. Johnson & Johnson put in the offer on Wednesday.

    The deal, the biggest in the European pharmaceutical industry in 13 years, would give J&J access to Actelion’s range of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product, Remicade for arthritis, faces cheaper competition.

    The Commission is expected to seek feedback from consumers and rivals before deciding whether to accept the offer, demand more or open a four-month long investigation.

    Full Content: Euro News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.